[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"valve-heart-stenosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:valve-heart-stenosis":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100622105","soft-foam-dressings-for-pressure-injury-prevention-of-cardiac-surgery-100622105",false,"NCT07379294","Soft Foam Dressings for Pressure Injury Prevention of Cardiac Surgery","Effectiveness of Using Soft Foam Dressings in Preventing Pressure Injuries During Cardiac Surger","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Scheduled to undergo cardiac surgery under general anesthesia\n* Use of cardiopulmonary bypass (CPB) during surgery\n* Expected surgical duration greater than 4 hours\n* Intact skin without pre-existing pressure injury prior to surgery\n\nExclusion Criteria:\n\n* Surgical position other than supine\n* Long-term bedridden status prior to hospital admission\n* Altered consciousness or inability to cooperate\n* History of stroke with residual limb weakness","ALL","18 Years",{"count":19,"type":20},80,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this study is to evaluate whether the application of soft foam dressings can reduce the occurrence of surgery-related pressure injuries among patients undergoing cardiac surgery. Specifically, this research aims to investigate differences in pressure injury outcomes before and after the intervention, and to assess the preventive effectiveness of soft foam dressings as an adjunctive skin-protection strategy.",[26,27,28,29,30,31,32,33,34],"CAD - Coronary Artery Disease","CABG","Valve Disease, Heart","Aortic Diseases","Valve Heart Stenosis","Aortic Aneurysm","Mitral Disease","AORTIC VALVE DISEASES","Aortic Dissection","NOT_YET_RECRUITING","2026-05-11",{"date":38,"type":39},"2026-05-14","ACTUAL",{"date":41,"type":20},"2026-05-31",{"date":43,"type":20},"2027-05-30",{"name":45,"class":46},"Shih,Wen-Chi","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100586608","mosaic-mitral-valve-long-term-outcomes-in-patients-under-65-100586608","NCT06917586","Mosaic Mitral Valve: Long-Term Outcomes in Patients Under 65","Long Term Patient Outcomes and Product Durability of the Mosaic Mitral Valve Bioprosthesis in Patients Under 65","MMV","Inclusion Criteria:\n\n* Received the Mosaic Mitral Valve Bioprosthetic at ProMedica Toledo Hospital\n* Under the age of 65\n\nExclusion Criteria:\n\n* Over the age of 65\n* Under the age of 18\n* Surgery performed at institutions outside of ProMedica Toledo Hospital","65 Years",{"count":57,"type":20},300,"OBSERVATIONAL","The safety and efficacy of the Mosaic bioprosthetic heart valves for cardiac valve replacement in the aortic position has been well documented throughout the literature. However, few studies assessing structural valve deficiency, patient outcomes and overall product performance in patients under the age of 65 exists for the Mosaic mitral valve bioprosthetic. This study aims to assess valve efficacy, stability, and post operative outcomes in patients who have received the Mosaic mitral valve prothesis at ProMedica Toledo Hospital and were under the age of 65.",[28,61,62,30],"Valve Replacement","Valve Regurgitation, Mitral",[64,65,66,67],"Mitral Valve","Bioprosthetic","Mosaic","Valvulopathy","RECRUITING","2026-02-18",{"date":71,"type":39},"2026-02-20",{"date":73,"type":39},"2025-01-01",{"date":75,"type":20},"2027-07-01",{"name":77,"class":46},"Michael Moront",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":78},"100296774","prospective-european-multicenter-study-on-aortic-valve-replacement-e-avr-registry-100296774","NCT03143361","Prospective European Multicenter Study on Aortic Valve Replacement: (E-AVR Registry)","Outcome Comparison of Different Surgical Strategies for the Management of Severe Aortic Valve Stenosis: Study Protocol of a Prospective Multicentre European Registry (E-AVR Registry)","E-AVR","Inclusion criteria\n\n* Age \\>18 yy\n* Isolated SAVS with or without concomitant aortic valve regurgitation\n* Isolated prosthetic aortic dysfunction\n* SAVS + coronary artery disease (CAD)\n* Prosthetic aortic dysfunction + CAD\n* Elective, urgent and emergent procedures\n* Endocarditic aetiology\n\nExclusion criteria\n\n* Patients undergoing concomitant mitral valve surgery, or tricuspid valve surgery, or aortic surgery (i.e. composite aortic valve and ascending aorta replacement with or without circulatory arrest), or atrial fibrillation surgery, or any other associated cardiac surgical procedure (with the exception of CABG)\n* Concomitant aortic root procedure (i.e. Bentall operation, David operation, homografts, autografts)\n* SAVR with techniques of aortic annular enlargement\n* Porcelain aorta\n* Pure aortic valve regurgitation\n* Percutaneous TAVR requiring surgical cut-down (i.e. failure to comply with a full percutaneous approach, thus configuring a \"hybrid procedure\")\n* Patient refusal",{"count":88,"type":20},8000,"Traditional and transcatheter surgical treatments of severe aortic valve stenosis (SAVS) are increasing in parallel with the improved life-expectancy. Recent randomized trials (RCTs) reported comparable or non-inferior mortality with transcatheter treatments compared to traditional surgery. However, RCTs have the limitation of being a mirror of the predefined inclusion\u002Fexclusion criteria, without reflecting the \"real clinical world\".\n\nTechnological improvements have recently allowed the development of minimally invasive surgical accesses and the use of sutureless valves, but their impact on the clinical scenario is difficult to assess because of the monocentric design of published studies and limited sample-size. A prospective multicentre registry including all patients referred for a surgical treatment of SAVS (traditional, through full-sternotomy; minimally-invasive; or transcatheter; with both \"sutured\" and \"sutureless\" valves) will provide a \"real-world\" picture of available results of current surgical options, and will help to clarify the \"grey zones\" of current guidelines.\n\nE-AVR is a prospective observational open registry designed to collect all data from patients admitted for SAVS, with or without coronary artery disease, in 16 cardiac surgery Centres located in six countries (France, Germany, Italy, Spain, Switzerland, and United Kingdom). Patients will be enrolled over a 2-year period and followed-up for a minimum of 5 years to a maximum of 10 years after enrolment. Outcome definitions are concordant with VARC-2 criteria and established guidelines. Primary outcome is 5-year all-cause mortality. Secondary outcomes aim at establishing \"early\" 30-day all-cause and cardiovascular mortality, as well as major morbidity, and \"late\" cardio-vascular mortality, major morbidity, structural and non-structural valve complications, quality of life and echocardiographic results.\n\nThe study protocol is approved by Local Ethics Committees. Any formal presentation or publication of data will be considered as a joint publication by the participating physician(s) and will follow the recommendations of the International Committee of Medical Journal Editors (ICMJE) for authorship.",[91,30],"Aortic Valve Stenosis",[93,94,95],"aortic valve stenosis","heart valves","heart surgery","2020-03-31",{"date":98,"type":39},"2020-04-03",{"date":100,"type":39},"2017-11-01",{"date":102,"type":20},"2029-10",{"name":104,"class":46},"University of Parma"]